Clinical Trial Update: Open-label Study of Curcumin C-3 Complex in Schizophrenia [Phase 1, Phase 2]

View source ↗

Summary

An open-label Phase 1/2 study of Curcumin C-3 Complex in schizophrenia and schizoaffective disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder
• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Curcumin C-3 Complex (curcumin)

Snippet

Sponsor: Woodbury, Michel, M.D. | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 1, Phase 2 | Status: COMPLETED